Literature DB >> 35861565

Oral Administration with Live Attenuated Citrobacter rodentium Protects Immunocompromised Mice from Lethal Infection.

Shuyu Wang1, Xue Xia1, Yue Liu1, Fengyi Wan1,2,3,4,5.   

Abstract

Enteropathogenic Escherichia coli (EPEC) and enterohemorrhagic E. coli (EHEC) are important causative agents for foodborne diseases worldwide. Besides antibiotic treatment, vaccination has been deemed as the most effective strategy for preventing EPEC- and EHEC-caused foodborne illnesses. Despite substantial progress made in identifying promising antigens and efficacious vaccines, no vaccines against EPEC or EHEC have yet been licensed. Mice are inherently resistant to EPEC and EHEC infections; infection with Citrobacter rodentium (CR), the murine equivalent of EPEC and EHEC, in mice has been widely used as a model to study bacterial pathogenesis and develop novel vaccine strategies. Mirroring the severe outcomes of EPEC and EHEC infections in immunocompromised populations, immunocompromised mouse strains such as interleukin-22 knockout (Il22-/-) are susceptible to CR infection with severe clinical symptoms and mortality. Live attenuated bacterial vaccine strategies have been scarcely investigated for EPEC and EHEC infections, in particular in immunocompromised populations associated with severe outcomes. Here we examined whether live attenuated CR strain with rational genetic manipulation generates protective immunity against lethal CR infection in the susceptible Il22-/- mice. Our results demonstrate that oral administration of live ΔespFΔushA strain promotes efficient systemic and humoral immunity against a wide range of CR virulence determinants, thus protecting otherwise lethal CR infection, even in immunocompromised Il22-/- mice. This provides a proof of concept of live attenuated vaccination strategy for preventing CR infection in immunocompromised hosts associated with more severe symptoms and lethality.

Entities:  

Keywords:  humoral immunity; immunocompromised hosts; live attenuated bacterium; oral administration

Mesh:

Substances:

Year:  2022        PMID: 35861565      PMCID: PMC9302154          DOI: 10.1128/iai.00198-22

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.609


  56 in total

1.  Humoral Immunity in the Gut Selectively Targets Phenotypically Virulent Attaching-and-Effacing Bacteria for Intraluminal Elimination.

Authors:  Nobuhiko Kamada; Kei Sakamoto; Sang-Uk Seo; Melody Y Zeng; Yun-Gi Kim; Marilia Cascalho; Bruce A Vallance; José L Puente; Gabriel Núñez
Journal:  Cell Host Microbe       Date:  2015-04-30       Impact factor: 21.023

2.  A plant-based oral vaccine to protect against systemic intoxication by Shiga toxin type 2.

Authors:  Sharon X Wen; Louise D Teel; Nicole A Judge; Alison D O'Brien
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-25       Impact factor: 11.205

3.  Cross-reactive protection against enterohemorrhagic Escherichia coli infection by enteropathogenic E. coli in a mouse model.

Authors:  Carla Calderon Toledo; Ida Arvidsson; Diana Karpman
Journal:  Infect Immun       Date:  2011-03-14       Impact factor: 3.441

4.  Organ specificity, colonization and clearance dynamics in vivo following oral challenges with the murine pathogen Citrobacter rodentium.

Authors:  Siouxsie Wiles; Simon Clare; James Harker; Alan Huett; Douglas Young; Gordon Dougan; Gad Frankel
Journal:  Cell Microbiol       Date:  2004-10       Impact factor: 3.715

5.  E. coli secreted protein F promotes EPEC invasion of intestinal epithelial cells via an SNX9-dependent mechanism.

Authors:  Andrew W Weflen; Neal M Alto; Virinchipuram K Viswanathan; Gail Hecht
Journal:  Cell Microbiol       Date:  2010-01-20       Impact factor: 3.715

Review 6.  Citrobacter rodentium-host-microbiota interactions: immunity, bioenergetics and metabolism.

Authors:  Caroline Mullineaux-Sanders; Julia Sanchez-Garrido; Eve G D Hopkins; Avinash R Shenoy; Rachael Barry; Gad Frankel
Journal:  Nat Rev Microbiol       Date:  2019-09-20       Impact factor: 60.633

7.  Towards an attenuated enterohemorrhagic Escherichia coli O157:H7 vaccine characterized by a deleted ler gene and containing apathogenic Shiga toxins.

Authors:  Jun Liu; Yang Sun; Shuzhang Feng; Lingwei Zhu; Xuejun Guo; Chong Qi
Journal:  Vaccine       Date:  2009-08-12       Impact factor: 3.641

8.  Novel fusion antigen displayed-bacterial ghosts vaccine candidate against infection of Escherichia coli O157:H7.

Authors:  Kun Cai; Wei Tu; Yuenan Liu; Tao Li; Hui Wang
Journal:  Sci Rep       Date:  2015-12-02       Impact factor: 4.379

9.  Metalloprotease NleC suppresses host NF-κB/inflammatory responses by cleaving p65 and interfering with the p65/RPS3 interaction.

Authors:  Andrea Hodgson; Eric M Wier; Kai Fu; Xin Sun; Hongbing Yu; Wenxin Zheng; Ho Pan Sham; Kaitlin Johnson; Scott Bailey; Bruce A Vallance; Fengyi Wan
Journal:  PLoS Pathog       Date:  2015-03-10       Impact factor: 6.823

Review 10.  Citrobacter rodentium: infection, inflammation and the microbiota.

Authors:  James W Collins; Kristie M Keeney; Valerie F Crepin; Vijay A K Rathinam; Katherine A Fitzgerald; B Brett Finlay; Gad Frankel
Journal:  Nat Rev Microbiol       Date:  2014-08-04       Impact factor: 60.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.